成人起病IgA血管炎肾炎的结局
该研究纳入202例肾活检确诊的IgA血管炎肾炎患者,按年龄分为18-34岁、35-64岁和≥64岁三组,中位随访44个月。老年组起病时进展至终末期肾病的比例高于中年组和年轻组,但在活检时肾功能独立者中各组肾脏生存无差异。男性、黑人种族、糖尿病、组织学慢性肾损伤及估算肾小球滤过率<30 ml/min是终末期肾病的危险因素。
要点
- 老年IgA血管炎患者起病时更易已进展至终末期肾病(23.9% vs 中年13.7% vs 年轻2.9%,P=0.002)。
- 活检时肾功能独立者中,各年龄组肾脏生存无差异。
- 男性、黑人种族、糖尿病、组织学慢性肾损伤及eGFR<30 ml/min是终末期肾病危险因素。
核心结论
- 老年IgA血管炎患者起病时更易已存在终末期肾病,但在活检时肾功能独立者中,各年龄组肾脏生存无差异。
- 活检时肾功能受损是后续发生终末期肾病的独立危险因素。
- 各专科中心在肾活检时机和管理上存在显著差异。
- 年轻成人的结局更接近儿童IgA血管炎。
研究设计与样本
- 研究纳入202例肾活检确诊的IgA血管炎肾炎患者,34%为18-34岁,43%为35-64岁,23%为≥64岁,中位随访44个月。
- 收集临床特征及进展至终末期肾病的数据,采用回归分析患者因素与终末期肾病的关系。
主要发现
- 老年组起病时终末期肾病比例为23.9%,中年组为13.7%,年轻组为2.9%(χ2 11.6,P=0.002)。
- 在活检时肾功能独立的患者中,各年龄组结局无差异。
- 男性、黑人种族、糖尿病、组织学慢性肾损伤证据及估算肾小球滤过率<30 ml/min是发生终末期肾病的危险因素。
- 本观察性研究中,68.3%的患者接受糖皮质激素治疗,56.9%接受额外免疫抑制治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: IgA vasculitis (IgAV) in adults has been relatively under-investigated. Since outcomes are worse in other forms of vasculitis with increasing age, we investigated the outcomes of IgAV comparing younger adults (18-34), middle-aged adults (35-64) and elderly patients (≥64 years) focusing on kidney outcomes. METHODS: We identified patients with renal biopsy-confirmed IgAV nephritis and collected data regarding clinical features and progression to end stage kidney disease (ESKD). The relationship between patient factors and ESKD was analysed by regression. RESULTS: We identified 202 cases, 34% aged 18-34, 43% aged 35-64 and 23% elderly (>64 years). Median follow-up was 44 months. Elderly patients were more likely to present with ESKD (23.9%) compared with middle-aged (13.7%) and younger adults (2.9%) (χ2 11.6, P = 0.002). In patients with independent kidney function at biopsy, there was no difference in outcomes between age groups. Male gender, Black ethnicity, diabetes, histological evidence of chronic renal damage and estimated glomerular filtration rate < 30 ml/min were risk factors for development of ESKD. In this observational study 68.3% of patients received glucocorticoids and 56.9% additional immunosuppression. CONCLUSION: Elderly patients with IgAV are more likely to have ESKD at presentation, but there is no difference in renal survival between age groups, among those presenting with independent renal function. Renal impairment at biopsy is an independent risk factor for subsequent development of ESKD. There is significant variability in the timing of kidney biopsy and management of these patients among specialist centres. Young adults have outcomes more in keeping with childhood IgAV.
引用
- Stanway J, Brown N, Pervez A, et al. IgA vasculitis nephritis-outcomes in adult-onset disease. Rheumatology (Oxford). 2025. PMID: 38273659. doi:10.1093/rheumatology/keae030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。